These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34690297)

  • 21. Premedication Use Before Infliximab Administration: A Cross-sectional Analysis.
    Picoraro J; Winberry G; Siegel CA; El-Matary W; Moses J; Grossman A; Park KT
    Inflamm Bowel Dis; 2017 Jan; 23(1):174-180. PubMed ID: 28002131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.
    Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.
    Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L
    J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inflammatory bowel disease: should all patients be premedicated when infliximab is administered to reduce infusion reactions and/or immunogenicity?].
    Ginard D; Mariño Z
    Gastroenterol Hepatol; 2008 Oct; 31(8):542-3. PubMed ID: 18928758
    [No Abstract]   [Full Text] [Related]  

  • 25. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease.
    Adler J; Sandberg KC; Shpeen BH; Eder SJ; Dhanani M; Clark SJ; Freed GL
    J Pediatr Gastroenterol Nutr; 2013 Jul; 57(1):35-8. PubMed ID: 23459317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
    Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab therapy in children and adolescents with inflammatory bowel disease.
    Veres G; Baldassano RN; Mamula P
    Drugs; 2007; 67(12):1703-23. PubMed ID: 17683171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
    Qazi T; Shah B; El-Dib M; Farraye FA
    Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
    Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
    World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
    Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K
    Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.
    Cheng J; Hamilton Z; Smyth M; Barker C; Israel D; Jacobson K
    Inflamm Bowel Dis; 2017 Oct; 23(10):1762-1773. PubMed ID: 28837517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    O'Meara S; Nanda KS; Moss AC
    Inflamm Bowel Dis; 2014 Jan; 20(1):1-6. PubMed ID: 24280879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study.
    Mälkönen T; Wikström A; Heiskanen K; Merras-Salmio L; Mustonen H; Sipponen T; Kolho KL
    Inflamm Bowel Dis; 2014 Aug; 20(8):1309-15. PubMed ID: 24918318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease-A Single Center Case-Control Study.
    Szymanska E; Dadalski M; Sieczkowska-Golub J; Jarzebicka D; Meglicka M; Osiecki M; Wiernicka A; Lebensztejn DM; Korczowski B; Kierkus J
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.
    Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse reactions to infliximab and the outcome of desensitization.
    Mourad AA; Boktor MN; Yilmaz-Demirdag Y; Bahna SL
    Ann Allergy Asthma Immunol; 2015 Aug; 115(2):143-6. PubMed ID: 26093777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
    Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
    J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of Severe Infusion Reactions Associated With Outpatient Infusion of Infliximab Without Premedications.
    Hutsell SQ; Wu M; Park KT
    J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):430-431. PubMed ID: 28937551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.
    Mazzuoli S; Tricarico D; Demma F; Furneri G; Guglielmi FW
    PLoS One; 2016; 11(11):e0166443. PubMed ID: 27851772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
    Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.